Reduction in Pediatric Rotavirus-related Hospitalizations After Universal Rotavirus Vaccination in Belgium

Raes, Marc; Strens, D; Vergison, Anne; Verghote, Marc; Standaert, Baudouin

doi:10.1097/inf.0b013e318214b811

Cited by 101 publications

(73 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed overall and age-dependent decline in RVGE hospitalizations and allcause AGE concur with previous reports. 13,[21][22][23] A recently published study from the Southern of Israel 23 has estimated a decline of 82%, 70% and 36% in RVGE hospitalization rates in Jewish children aged 0-11, 12-23 and 24-59 months respectively, while the respective decrease was estimated at 70%, 21% and 14% among Bedouin children. 23 We found no significant difference in the detection of rotavirus between Jewish and Arab children either before or after the introduction of universal rotavirus vaccines.…”

Section: Discussionmentioning

confidence: 99%

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

Muhsen

Rubenstein

Kassem

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Universal rotavirus vaccination with RotaTeq was introduced in Israel in December 2010. We examined hospitalization rates of children under 5 years of age due to all-cause and rotavirus gastroenteritis, both before and 3 years after universal introduction of the vaccination. An ongoing hospital-based surveillance network that was established in November 2007, accessed information regarding hospitalization of children due to gastroenteritis (n D 6205) in 3 hospitals in northern Israel, with an annual average of about 60,000 children under 5 years of age living in the catchment area of these hospitals. Stool samples were tested for rotavirus by immunochromatography. Compared to the period preceding implementation of the universal rotavirus vaccination (2008)(2009)(2010), hospitalizations due to rotavirus gastroenteritis in children <5 years of age decreased significantly, by 55% (95% CI 43%-67%) during the period of universal vaccination (2011-2013), a decrease that was sustained throughout the 3 year period. This reduction was greater in children aged 0-23 months (60-61%) than in toddlers aged 24-59 months (36%). A 32% (95% CI 21%-45%) decrease in the incidence of all-cause gastroenteritis was also observed. During the period preceding universal vaccination, rotavirus diarrhea showed typical winter seasonality, with highest incidence in December. However, the winter peak was substantially blunted during the period of universal immunization. Surveillance of rotavirus gastroenteritis should continue to assess the long-term impact of such a program. Our findings are of relevance to high and middle-income countries considering the introduction of a universal rotavirus immunization program.

show abstract

Section: Discussionmentioning

confidence: 99%

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

Muhsen

Rubenstein

Kassem

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…[17][18][19][20] Belgium introduced rotavirus vaccination in November 2006, with an uptake of 85% in the first year 21 and 89% in the second year. 22 This high vaccine uptake is maintained throughout subsequent years where parents are asked for a co-payment of the vaccine of 11.6€ per dose. 23 We have previously investigated the change in winter pediatric hospitalizations from before to after the introduction of rotavirus vaccination.…”

Section: Introductionmentioning

confidence: 99%

“…23 We have previously investigated the change in winter pediatric hospitalizations from before to after the introduction of rotavirus vaccination. 22 By reducing the seasonal influx of urgent RVGE cases into pediatric hospitals, the vaccine could help to reduce the winter pressure on healthcare resources and staff, offering potential wider benefits beyond reduced healthcare costs and quality-of-life gains in improving hospital quality of care (QoC). Such benefits would accrue to patients and their families, staff and hospital managers.…”

Section: Introductionmentioning

confidence: 99%

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

Standaert

Alwan²,

Strens

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

During each winter period hospital emergency rooms and pediatric wards are often overwhelmed by high patient influx with infectious diseases leading to chaotic conditions with poor quality of care (QoC) delivery as a consequence. The conditions could be improved if we were able to better control the influx by introducing for instance better prevention strategies against some of the most frequent infectious diseases. New prevention strategies using vaccination against rotavirus infection were introduced in Belgium in November 2006. We developed a measure of hospital QoC suitable for assessing the impact of pediatric rotavirus vaccination. The study is retrospective collecting routine data on bed and staff management in one pediatric hospital in Belgium. The data were divided in pre-and post-vaccination periods during rotavirus-epidemic and non-epidemic periods. The scores were constructed using Explanatory Factor Analysis (EFA). All patients enrolled were admitted to the pediatric ward over the period from 1 January 2004 to 31 December 2009. The results of the epidemic period indicated that bed-day occupancy, bed-day turnover and unplanned readmissions for acute gastroenteritis were lower in the post-vaccination compared with the pre-vaccination periods. The QoC scores were therefore significantly lower (indicating improved QoC) after the introduction of rotavirus vaccination, compared with pre-vaccination. The data suggests that the reduction in the winter peak of rotavirus-related hospitalizations after the introduction of the vaccine reduces pressure on hospital resources and improves the quality of hospital care. The findings should be further tested in similar settings.

show abstract

“…Typically, these studies compared various outcomes, such as the numbers of RVGE cases, RVGE-related hospitalizations, and/or emergency department visits, that occurred during the pre-vaccination period with those that occurred during a specific period after widespread or universal introduction of a rotavirus vaccination program. Studies conducted in the Australian state of Queensland [27] and in European countries [28][29][30] involved rotavirus vaccination programs with either the monovalent or pentavalent rotavirus vaccine, whereas studies conducted in the US generally focused only on the pentavalent vaccine (reviewed elsewhere [31,32] ). Rotavirus vaccine RIX4414 was generally well tolerated in clinical trials, with an overall tolerability profile similar to that of placebo.…”

Section: Clinical Profile Of Rotavirus Vaccine Rix4414mentioning

confidence: 99%

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries

Plosker¹

2012

Drugs R D

View full text Add to dashboard Cite

Reduction in Pediatric Rotavirus-related Hospitalizations After Universal Rotavirus Vaccination in Belgium

Abstract: Pediatric rotavirus vaccination in Belgium significantly reduced rotavirus-related hospitalizations in the first and second years after introduction.

Cited by 101 publications

References 22 publications

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries

Contact Info

Product

Resources

About